Quintiles’ Risk Mitigation Strategy Recognized in CSO50
RESEARCH TRIANGLE PARK, N.C - Thursday, February 26th 2015 [ME NewsWire]
(BUSINESS WIRE) -- Quintiles announced today that it has been named to the 2015 CSO50 by IDG's CSO magazine in recognition of the company’s risk mitigation strategy managing Windows XP security challenges.
CSO commended the Quintiles team for its innovative defense-in-depth model which minimized security risks for business-critical applications dependent on Windows XP, delivering secure and segmented platforms while protecting critical company assets.
“This was an innovative solution to a problem that presents significant security concerns for many organizations around the world,” said Quintiles Chief Information Security Officer Patricia Collins Weedon. “Quintiles has launched many innovative customer solutions that require our team to think beyond current cyber security, compliance, and data protection challenges. We are honored to receive this award in recognition for the sterling work our world-class security team undertakes 24 x 7,” Weedon added.
Each year, the CSO50 Awards recognize 50 organizations for security projects and initiatives that demonstrate outstanding business value and thought leadership. Nominations are scored on a uniform set of criteria by a panel of judges including security leaders, industry experts, and academics. The final winning selections are made by CSO's editors based on this scoring process.
“For the third year in a row, outstanding organizations demonstrating innovation, creativity and understanding of business value in security were chosen from a large pool of submissions." said Joan Goodchild, editor, CSO. "We congratulate this year's CSO50 winners and applaud them for setting the bar high for security's role in providing value and ROI in business."
Quintiles (NYSE: Q), a Fortune 500 company, is the world’s largest provider of biopharmaceutical development and commercial outsourcing services. With a network of more than 32,000 employees conducting business in approximately 100 countries, we helped develop or commercialize all of 2013’s top-100 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit www.quintiles.com.
Click here to subscribe to Mobile Alerts for Quintiles.
Phil Bridges, Media Relations (firstname.lastname@example.org)
+ 1.919.998.1653 (office)
Karl Deonanan, Investor Relations (InvestorRelations@quintiles.com)